Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 12—December 2007
Letter

Human Papillomavirus Vaccination Strategies

Santiago Pérez Cachafeiro*Comments to Author 
Author affiliation: *Galician Agency for Health Technology Assessment, Santiago de Compostela, Spain

Main Article

Table

Cost-effectiveness analysis of alternative human papillomavirus vaccination strategies*

Strategy Discounted
 Incremental†
Cost QALY Cost QALY ICER ($/QALY)‡
No vaccination $72,659,302 2,698,711 – – –
12-y-old girls $74,042,990 2,699,178 $1,383.688 467 Dominated
18-y-old women + 18–24-y-old female catch-up $73,553,847 2,699,192 $894,545 481 $1,860
15-y-old girls + 15–24-y-old female catch-up $73,895,046 2,699,214 $341,199 22 $15,509
12-y-old girls and boys $78,707,825 2,699,327 $4,812,779 113 Dominated
12-y-old girls + 12–24-y-old female catch-up $74,815,667 2,699,343 $920,621 129 $7,137
18-y-old women and men + 18–24-y-old female and male catch-up $77,535,383 2,699,385 $2,719,716 42 $64,755
15-y-old girls and boys + 15–24-y-old female and male catch-up $78,455,750 2,699,404 $920,367 19 $48,440
12-y-old girls and boys + 12–24-y-old female catch-up $79,746,357 2,699,461 $1,290,607 57 $22,642
12-y-old girls and boys + 12–24-y-old female and male catch-up $81,761,210 2,699,506 $2,014,853 45 $44,775

*QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; $, US dollars.
†Based on discounted costs reported by Elbasha et al. (1).
‡Compared with the preceding nondominated strategy. Strategy A is dominated if there exists another strategy, B, that is more effective and less costly than strategy A.

Main Article

References
  1. Elbasha  EH, Dasbach  EJ, Insinga  RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41. DOIPubMedGoogle Scholar
  2. Clifford  GM, Gallus  S, Herrero  R, Munoz  N, Snijders  PJF, Vaccarella  S, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991–8. DOIPubMedGoogle Scholar
  3. HBV vaccination programmes in adolescent population 1996–1997 period [in Spanish]. Boletín Epidemiológico Semanal Instituto de Salud Carlos III. 1998;6:209–10.

Main Article

Page created: July 06, 2010
Page updated: July 06, 2010
Page reviewed: July 06, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external